Used extensively in the field of targeted cancer therapy, this compound plays a crucial role in antibody-drug conjugates (ADCs). It connects the cytotoxic agent MMAE to a monoclonal antibody through a Val-Cit-PABC linker, ensuring precise delivery to cancer cells. The acetylene group enhances stability and efficiency in conjugation processes. Once inside the target cells, the linker is cleaved by cathepsin B, releasing MMAE to induce apoptosis. This approach minimizes damage to healthy tissues, improving the therapeutic window and reducing side effects in treatments for various cancers, including lymphoma and solid tumors.